J.ophthalmol.(Ukraine).2018;5:39-44.

https://doi.org/10.31288/oftalmolzh201853944

Received: 16 July  2018; Published on-line: 26 October 2018


Clinical efficacy of combination treatment for advanced-stage axial diabetic optic neuropathy

M.A. Karliychuk, Cand Sc (Med)

Higher State Educational Establishment of Ukraine «Bukovinian State Medical University»; 

Chernivtsi (Ukraine)

E-mail: mari13karli@gmail.com

TO CITE THIS ARTICLE: Karliychuk MA. Clinical efficacy of combination treatment for advanced-stage axial diabetic optic neuropathy. J.ophthalmol.(Ukraine).2018;5:39-44. https://doi.org/10.31288/oftalmolzh201853944

 

Background: There is no standard of therapy for diabetic optic neuropathy (DON) which takes into consideration the type and stage of the disease.

Purpose: To assess the clinical efficacy of combined adjunct treatment with  thioctic acid, a combination of vitamins В1, В6, and В12, ethyl methyl hydroxypyridine succinate, citicoline and brimonidine tartrate in the management of advanced-stage axial DON.

Materials and Methods: Forty patients (63 eyes) were followed up after being diagnosed with advanced-stage axial DON. The adjunct group was composed of 20 patients (31 eyes) who were administered two courses a year of the following treatment as a combined adjunct to hypoglycemic therapy: 1) a 600 mg intramuscular injection of thioctic acid (Berlithion), daily for 21 days, followed by switching to oral regimen, at a dose of one 300 mg tablet twice a day for 21 days, (2) a 2 ml intramuscular injection of Milgamma, once per 3 days for 21 days, followed by switching to oral regimen,  one tablet thrice a day for 21 days, (3) a 100 mg intramuscular injection of ethyl methyl hydroxypyridine succinate (Armadine), twice a day for 14 days, and (4) a 500-mg intravenous bolus of citicoline (Ceraxon), twice a day for 14 days, followed by switching to oral regimen,  500 mg daily for a month. In addition, they were administered topical brimonidine tartrate 0.2%, 1-2 drops twice a day on a constant basis. The control group (20 patients; 32 eyes) received hypoglycemic therapy only. In addition to routine eye examination, retinal and optic nerve optical coherence tomography and electrophysiology were performed. Patients underwent an examination at baseline and 1.5, 6, 7.5, 12, 13.5, 24 and 25.5 months after treatment.

Results: The combined adjunct treatment was found to result in improvements in study indices in 83.9% of patients of the adjunct group, with 191% better visual acuity (p < 0.05), 235.0% lower electrically evoked phosphene thresholds (p < 0.05), 38.5% less ganglion cell complex (GCC) focal loss volume (FLV), and 36.5% less thickness of the lamina cribrosa compared to controls at 25.5 months.

Conclusion: Our combination treatment was found to be clinically efficacious in improving structural and functional characteristics of the optic nerve in patients with advanced-stage axial DON.

Keywords: axial diabetic optic neuropathy, advanced stage, comprehensive treatment, efficacy

 

References

  1. Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012;6:CD007543
    Crossref   Pubmed
  2. Kotov SV, Isakova EV, Lizhdvoi VYu, et al. [Efficacy of cocarnit in diabetic neuropathy]. Zhurnal nevrologii i psikhiatrii. 2018;1:37–42. Russian
    Crossref   Pubmed
  3. Gonçalves NP, Vægter CB, Pallesen LT. Peripheral Glial Cells in the Development of Diabetic Neuropathy. Front Neurol. 2018 May 2;9:268
    Crossref   Pubmed
  4. Hosseini A, Abdollahi M. Diabetic neuropathy and oxidative stress: therapeutic perspectives. Oxid Med Cell Longev. 2013;2013:1–5. doi: 10.1155/2013/168039
    Crossref   Pubmed
  5. Effect of intensive treatment of hyperglycemia on microvascular complications of type 2 diabetes in ACCORD: a randomized trial. Lancet. 2010 Aug 7; 376(9379): 419-30
  6. Morgunov LY. [Alpha-lipoic acid drugs in the treatment of diabetic neuropathy].   Meditsinskii sovet. 2014;17:90–4. Russian
  7. Strokov IA, Fokina AS. [Novel potential for the treatment of diabetic complications]. RMZh.  2012;20:88–91. Russian
  8. Chukanova EI, Chukanova AS. [Alpha-lipoic acid in the treatment of diabetic polyneuropathy]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2018;1:103–9. Russian
    Crossref   Pubmed
  9. Han T, Bai J, Liu W, Hu Y.  A systematic review and meta-analysis of alpha-lipoic acid in the treatment of diabetic peripheral neuropathy. Eur J Endocrinol. 2012; 167(4):465–71
  10. Jayabalan B, Low LL. Vitamin B supplementation for diabetic peripheral neuropathy. Singapore Med J. 2016;57(2):55-9
  11. Papanas N, Ziegler D. Efficacy of alpha-lipoic acid in diabetic neuropathy. Expert Opin Pharmacother. 2014; 15:2721–31
  12. Stracke H, Lindemann A, Federlin K.  A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. Exp Clin Endocrinol Diabetes. 1996; 104(4): 311–6
  13. Ziegler D, Low PA, Litchy WJ, et al. Efficacy and Safety of Antioxidant Treatment With α-Lipoic Acid Over 4 Years in Diabetic Polyneuropathy. The NATHAN 1 trial. Diabetes Care. 2011 Sep;34(9):2054–60.
  14. Bezditko PA, Karliychuk MA. Clinical and OCT features of different types and stages of diabetic optic neuropathy. J Ophthalmol (Ukraine). 2018; 1:43–8. 
  15. Bezditko PA, Karliychuk MA. [Clinical-diagnostic criteria of different types of nerve damage in patients with diabetes mellitus]. Arkhiv oftalmologii Ukrainy. 2017; 5(3):18–22. Ukrainian
  16. Bezditko PA, Karliychuk MA, Lukhanin OO, Zavoloka OV. [Peculiarities of spectral coherence tomography using for investigation of the scleral lamina cribrosa thickness and the area of its scleral channel]. Kharkivska khirurgichna shkola. 2017; 3–4:63-9. Ukrainian
  17. Amano S, Kaji Y, Oshika T, et al.  Advanced glycation end products in human optic nerve head. Br J Ophthalmol. 2001 Jan; 85(1):52–5
  18. Terai N, Spoerl E, Haustein M, et al. Diabetes mellitus affects biomechanical properties of the optic nerve head in the rat. Ophthalmic Res. 2012;47:189–94
  19. Saylor M, McLoon LK, Harrison AR, et al.  Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review. Arch Ophthalmol. 2009; 127(4):402–6
  20. Simó R, Hernández C; European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR). Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives. Trends Endocrinol Metab. 2014; 25:23–33
  21. Volchegorskiy IA, Moskvichiova MG, Chaschchina EN. [Effect of Mexidolum on manifestations of symmetric distal polyneuropathy in diabetic patients with diabetic foot syndrome]. Farmateka. 2007; 20:76–9. Russian
  22. Gorshkov IP, Chernykh TM. [Treatment with ethyl methyl hydroxypyridine succinate combined with B-vitamin-like substances in type 2 diabetes patients with diabetic polyneuropathy]. Molodoi uchenyi. 2015;22:255–60. Russian
  23. Grieb P. Neuroprotective properties of citicoline: Facts, doubts and unresolved issues. CNS Drugs. 2014 Mar;28(3):185-93
  24. Zerbini G, Bandello F, Lattanzio R, et al. In vivo Evaluation of Retinal and Choroidal Structure in a Mouse Model of Long-Lasting Diabetes. Effect of Topical Treatment with Citicoline. J Ocul Dis Ther. 2015;3(1):1–8
    Crossref   Pubmed
  25. Oshitari T, Yoshida-Hata N, Yamamoto S.  Effect of neurotrophic factors on neuronal apoptosis and neurite regeneration in cultured rat retinas exposed to high glucose. Brain Res. 2010; 1346:43–51
    Crossref   Pubmed
  26. Liu Y, Li N, Ran XW. Clinical effect of ligustrazine combined with citicoline for treatment of diabetic peripheral neuropathy. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008 Jul;28(7):606-9